

## County Durham & Tees Valley Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Thursday 11<sup>th</sup> July 2019**

### Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **O**- Second line / alternative green drug
- A** **Amber Specialist initiation / recommendation drug**. Can be recommended by a specialist for initiation in primary care; or be initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs
- X** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within County Durham & Darlington.
- Q** **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in County Durham & Darlington.
- P** **Unclassed Drug** - Drugs that do not fall into one of the above categories

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meetings</b>				
None				
<b>2) New Requests</b>				
<b>Metformin</b>	✓ <b>A</b>	✓		Requested by NTHFT for use in polycystic ovary syndrome in patients not receiving fertility treatment from secondary care.  <b>Decision:</b> approved as Amber Specialist initiation / recommendation drug
<b>Magnesium sulphate 10% solution in a pre-filled syringe (5g magnesium sulphate (20mmol) in 50ml solution, in a 60ml syringe)</b>			✓	Requested by STFHT for be used as a hospital only drug for management of pre-eclampsia and eclampsia in pregnancy. Noted unlicensed. There are other injection formulations of magnesium sulphate already included in local formularies for this indication but these require dilution of the injection vial/ampoules to prepare. the infusion. These magnesium sulphate pre-filled syringes are ready to use with no further dilution hence will save time and reduce errors in an emergency situation.  <b>Decision:</b> deferred pending discussion at STFHT D&T

## DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>Fresubin thickened level 2</b>			✓	Requested by STHFT. Fresubin® thickened is a high protein, high energy textured modified Stage 2 (custard consistency) oral nutritional supplement. There are currently no other supplement products available that are suitable for patients who require level 2 fluids. Currently having to use products that are of a thicker consistency (level 3) or products that are not specifically designed as a dysphagia product (ie not amylase resistant) therefore its consistency cannot be guaranteed.  <b>Decision:</b> deferred pending discussion at STHFT D&T
<b>3) New formulations &amp; extensions to use</b>				
None				
<b>5) Products considered by NICE</b>				
<b>TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis</b>	✓ <b>R</b>			The formulary will reflect the TAG – CCGs are the responsible commissioner.
<b>TA575: Tildrakizumab for treating moderate to severe plaque psoriasis</b>	✓ <b>R</b>			The formulary will reflect the TAG – CCGs are the responsible commissioner.
<b>TA576: Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)</b>		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner – NICE did not recommend use.
<b>TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer</b>		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner – NICE did not recommend use.
<b>TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA582: Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)</b>		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner – NICE did not recommend use.
<b>TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes</b>	✓ <b>G</b>			The formulary will reflect the TAG – CCGs are the responsible commissioner.
<b>TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA585: Ocrelizumab for treating primary progressive multiple sclerosis</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>7) Appeals against earlier decisions by the APC</b>				
None				
<b>8) Products considered by NTAG</b>				
None				
<b>8) Miscellaneous decisions by the APC</b>				
<b>Chapter 1 to 5 of formulary</b>				Recommendations for changes to Chapter 1 to 5 to harmonise existing formularies into one APC formulary were approved.

The following guidelines were presented to and approved at the July 2019 meeting of the APC:

- County Durham & Darlington Paediatric Asthma Guidelines – adoption in Tees

The following Green+ drug information leaflets were presented to and approved at the May 2019 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the July 2019 meeting of the APC:

- County Durham & Darlington Azathioprine (updated)
- TEWV Shared Care for Valproate to Support Valproate Pregnancy Prevention Programme (updated)
- TEWV Anxiety Medication Pathway for Adults (updated)
- TEWV Safe Lithium Prescribing and Shared Care (updated)

Other documents presented to and approved at the July 2019 meeting of the APC:

- County Durham and Tees Valley APC Terms of Reference